Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Tradr 2X Long Snps Daily ETF (SNPX)

Tradr 2X Long Snps Daily ETF (SNPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
AI Data Center by Gorodenkoff via Shutterstock
Trade 3 Stocks Driving the $500B AI Infrastructure Boom with 2X Leverage Barchart Impact - Thu Jan 29, 9:22AM CST

Tradr ETFs has launched three new 2X leveraged ETFs (LITX, CSEX, and SNPX) to help active traders amplify daily exposure to infrastructure leaders Lumentum, Celestica, and Synopsys as they he

LITX : 42.02 (+5.39%)
SNPX : 27.11 (-14.08%)
SNPS : 419.14 (-8.46%)
CLS : 297.45 (+4.33%)
CSEX : 16.45 (+8.62%)
LITE : 435.10 (+2.76%)
Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex PR Newswire - Tue Nov 18, 2025

Newly listed options deliver another tool for traders to express their views on BE, CLS, NNE & SNPS

BEX : 32.48 (+15.71%)
SNPX : 27.11 (-14.08%)
NNEX : 13.36 (+13.32%)
CSEX : 16.45 (+8.62%)
Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys PR Newswire - Tue Nov 11, 2025

Four funds represent first-to-market strategies offering 200% exposure on trending growth stocks

BEX : 32.48 (+15.71%)
SNPX : 27.11 (-14.08%)
NNEX : 13.36 (+13.32%)
CSEX : 16.45 (+8.62%)
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study PR Newswire - Thu Sep 7, 2023

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...

SNPX : 27.11 (-14.08%)
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis PR Newswire - Wed Jul 19, 2023

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 27.11 (-14.08%)
Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities PR Newswire - Tue Mar 7, 2023

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 27.11 (-14.08%)
Wall Street - shutterstock_1321462400
Pre-Market Brief: Stocks Mixed As Recession, Rate Hike Fears Persist Barchart - Mon Dec 19, 2022

March S&P 500 futures (ESH23) are trending up +0.39% this morning after three major U.S. benchmark indices slid for a third successive session and suffered a second consecutive week of losses on Friday...

TSLA : 421.96 (+0.04%)
HEXO : 0.7100 (+2.45%)
SNPX : 27.11 (-14.08%)
CTLT : 63.48 (unch)
ESH23 : 3,957.05s (-0.09%)
ARDX : 7.74 (-0.64%)
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease PR Newswire - Fri Dec 16, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 27.11 (-14.08%)
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results PR Newswire - Wed Sep 28, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

SNPX : 27.11 (-14.08%)
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network PR Newswire - Fri Aug 12, 2022

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

SNPX : 27.11 (-14.08%)

Barchart Exclusives

General Motors Just Raised Its Dividend 20%. Does That Make GM Stock a Buy? Barchart - Tue Feb 3, 6:30PM CST
A richer dividend and cheap valuation put GM back on income investors’ radar despite restructuring noise. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot